Two-level ESPB in Total Knee Arthroplasty
CompletedPhase 4NCT06470542
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Effect of two-level ESPB in Total Knee Arthroplasty
Study details
- Official title
- Two-level Erector Spinae vs iPack With ACB Plane Block in Total Knee Arthroplasty
- Interventions
- Drug: 2 x 20 ml of Ropivacaine 0.2% Injectable Solution
- Drug: 2 x 20ml of Ropivacaine 0.2% Injectable Solution
- Sponsor
- Poznan University of Medical Sciences
- Start date
- 2024-11-07
- Primary completion
- 2025-08-05
- Sex
- All
- Age range
- from 65 Years to 100 Years
- Results posted
- No results posted in this snapshot
- Countries
- Poland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * patients scheduled for total hip arthroplasty * patients aged \>65 and \<100 years * patients able to provide informed consent * patients able to reliably report symptoms to the research team Exclusion Criteria: * inability to provide first-party consent due to cognitive impairment or a language barrier
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06470542